2013, Number 3
<< Back Next >>
Rev Esp Med Quir 2013; 18 (3)
Medical Treatment Guides of Non-Smaill cell Lung Cancer at ISSSTE(Second Part)
Erazo VSAA, Hernández HCA, Aldaco SF, González EF
Language: Spanish
References: 7
Page: 241-247
PDF size: 355.34 Kb.
ABSTRACT
No abstract
REFERENCES
Felip E, Gridelli C, Baas P, Rosell R, Stahel R & Panel members 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann Oncol 2011;22:1507-1519. Doi:10.1093/ annonc/mdr150
Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non small cell lung cancer: The Southwest Oncology Group Experience. J Clin Oncol 1991;9:1618-1626.
Paesmans M, Sculier JP, Libert P, Bureau G, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: Univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. J Clin Oncol 1995;13:1221-1230.
Fisher S, Al-Fayea TM, Winget M, Gao H. Uptake and tolerance of chemotherapy in elderly patients with small cell lung cancer and impact on survival. J Cancer Epidemiol 2012;2012.
Azzoli CG, Baker S, Temin S, Pao W, et al. American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV non-small-cell lung cancer. J Clin Oncol 2011;29:3825-3831.
Smith IE, O'Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non-small cell lung cancer: A randomized trial of three vs six courses of mitomycin, vinblastine ans cisplatin. J Clin Oncol 2001;19:1336-1343.
Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy vs continuous therapy followed by second-line therapy in advanced IIIB/IV non-small cell lung cancer. J Clin Oncol 2002;20:1335-1343.
Full text